NatiVita will produce innovative forms of insulin in Belarus

NatiVita has signed an agreement with the Russian company GEROPHARM on scientific and production cooperation and transfer of technologies for the production of innovative forms of insulin at the facilities of NatiVita (Beshenkovichi, Vitebsk region). The signing of the contract took place on 17th July at the GEROFARM production platform in Pushkin (St. Petersburg).

Cooperation between the two companies will cover the production of genetically engineered human insulin and insulin analogues. NatiVita will be the first non-state local producer of cartridge forms in Belarus, which will optimize the expenditure of budgetary funds for the purchase of insulin from foreign manufacturers. The implementation of this project will allow to realize in real clinical practice the plans of Belarusian doctors to improve the treatment of diabetes, to meet the needs of patients in the modern form of insulin.

“The NatiVita team strives to do everything to make the latest approaches to the treatment of diseases available to as many people as possible, and we are glad that our partner in the direction of diabetes was GEROPHARM, which has a strong expertise and its own technologies in the field of insulin production.

The start of insulin production using the technology of our Russian partner and their introduction to the market of Belarus is the first stage of cooperation. Further projects include expanding the portfolio of drugs for the treatment of diabetes and increasing the availability of modern therapy for Belarusian patients”, — said the Chairman of the Board of Directors of NatiVita Vladimir Sychov.